More than eighty percent of pharmaceutical companies have good results in the first three quarters, and the performance of medical devices, CXO and other segments is eye-catching

【Pharmaceutical Network Market Analysis】Up to now, 36 pharmaceutical companies have disclosed their performance forecasts for the first three quarters of 2022, and more than 80% of pharmaceutical companies are expected to have a good performance, of which 6 pharmaceutical companies are expected to double
their net profits in the first three quarters.
From the perspective of their subdivisions, medical devices, CXO and other tracks have performed well
.
Among them, in the field of medical devices, BGI expects that the operating income in the first three quarters of this year will be about 3.
281 billion to 3.
441 billion yuan, a year-on-year increase of 15.
26%-20.
88%; It is expected to achieve a net profit attributable to about 1.
893 billion to 2.
023 billion yuan, a year-on-year increase of 311.
8% to 340.
08%.

For the growth of performance, the company said that it is mainly benefiting from the development of the industry, the rapid development of the gene sequencing industry and the expansion of the application field of laboratory automation equipment have greatly increased the demand for the company's products; In addition, it also benefits from the company's years of accumulation of research and development strength, management ability improvement and market channel expansion
.
In the CXO field, WuXi AppTec, a leading company, expects to achieve operating income of about 28.
395 billion yuan in the first three quarters of 2022, a year-on-year increase of about 71.
87%; It is expected to achieve a net profit of about 7.
378 billion yuan, a year-on-year increase of about 107.
12%.

Regarding the growth, WuXi AppTec said that the company continued to strengthen WuXi AppTec's unique integrated CRDMO (contract research, development and production) and CTDMO (contract testing, development and production) business models.
Under the influence of the continuous and repeated epidemics in many places, give full play to the advantages of global layout, multi-location operations and full industry chain coverage, and formulate and efficiently implement business continuity plans in a timely manner to ensure the achievement
of the company's overall performance goals.
In addition, there are also companies
in the large infusion and traditional Chinese medicine industries that are expected to perform well.
For example, Kelun Pharmaceutical, a large infusion head company, expects a net profit of 1.
31-1.
44 billion yuan in the first three quarters of 2022, a year-on-year increase of 55%-70%.

The company said that during the reporting period, the company made every effort to expand the infusion and non-infusion product market, continued to optimize the product structure, increased the sales of newly approved products, and increased
profits year-on-year.
In addition, the company's holding subsidiary, Yili Chuanning Biotechnology Co.
, Ltd.
, the market price of major products increased, the profit increased year-on-year, and the company's innovative research and development projects reached cooperation agreements and paid exclusive licenses, which increased revenue and profits
.
Traditional Chinese medicine enterprise Kangyuan Pharmaceutical Co.
, Ltd.
also achieved a net profit increase of nearly 50% in the third quarter of 2022, and its third quarterly report showed that the company achieved operating income of 1.
028 billion yuan, a year-on-year increase of 26.
25%; the net profit was 70.
2172 million yuan, a year-on-year increase of 47.
48%; Basic earnings per share were $
0.
12.
Industrial Securities said in the research report that the pharmaceutical sector has entered the third quarterly performance disclosure period, and the cost performance of the sector is outstanding
.
In terms of segmentation, it is expected that the upstream life sciences, ophthalmic optometry, some medical devices, CXO (pharmaceutical outsourcing services), some vaccines, pharmacies and other sectors are expected to achieve good performance growth
in the third quarter.
Recently, while the performance of many pharmaceutical companies is gratifying, the pharmaceutical sector index has also ushered in a rapid rise, with a cumulative increase of more than 14%
in the past five trading days.
The analysis believes that many factors in the industry support the bottom of the pharmaceutical upward
.
In addition to the performance support, the recent benefits include the early "moderate regulation of the price of dental implant services" and "the collection of spinal consumables is better than expected", etc.
have been released one after another, in addition, the pharmaceutical sector has a large adjustment in the early stage, most innovative drug companies are almost cut or more, and the overall valuation of the sector tends to be reasonable
after the valuation returns.
Guohai Securities believes that the market's pessimistic expectations for centralized procurement have been reversed, and the overall atmosphere and sentiment of the industry have also improved
rapidly.
Therefore, as far as the future market is concerned, the long-term value of the pharmaceutical sector may usher in a return
.
In the direction of segmentation, the landing of innovative drug achievements, the concentration of medical device market share to the leader, and the release of lagging demand for medical services are expected to bring certain market opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.